Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

Michael B. Atkins, Manuel Hidalgo, Walter M. Stadler, Theodore F. Logan, Janice P. Dutcher, Gary R. Hudes, Young Park, Song Heng Liou, Bonnie Marshall, Joseph P. Boni, Gary Dukart, Matthew L. Sherman

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences